Pilot study of H₂ therapy in Parkinson’s disease: a randomized double-blind placebo-controlled trial.
In a laboratory model, total Unified Parkinson's Disease Rating Scale (UPDRS) scores in the H₂-water group (n=9) improved (median, -1.0; mean ± standard deviation, -5.7 ± 8.4), whereas UPDRS scores in the placebo group (n=8) worsened (median, 4.5; mean ± standard deviation,…
Read Article